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Introduction
Helicobacter pylori (H. pylori) is a curved gram-
negative, rod-shaped, flagellate, microaerophilic spiral 
bacillus and presently classified as a group 1 carcinogen 
by the World Health Organization International Agency 
for Research on Cancer (WHO/IARC). H. pylori plays an 
important role in chronic gastritis, peptic ulcers, gastric 
lymphoma and the development of adenocarcinoma 
(Malfertheiner et al., 2012). Gastric cancer is the second 
most common cancer in the world while long-standing 
infection with H. pylori significantly increases the risk of 
developing this disease. 
H. pylori as one of the most common chronic bacterial 
infections worldwide is colonized in the stomachs of about 
50-60% of the world’s population. Bacterial infection has 
been spread over approximately 50% of the developed 
countries and 80% of the population living in developing 
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Abstract
 Helicobacter pylori as the second most common cause of gastric cancer in the world infects approximately 
half of the developed countries population and 80% of the population living in developing countries. Integrons 
as genetic reservoirs play major roles in dissemination of antimicrobial resistance genes. To the best of our 
knowledge, this is the first study to report carriage of class 1 and 2 integrons and associated gene cassettes 
in H. pylori isolates from Iran. This cross-sectional study was conducted in Tehran among 110 patients with 
H. pylori infection. Antimicrobial susceptibility testing (AST) for H. pylori strains were assessed by the micro 
broth dilution method. Class 1 and 2 integrons were detected using PCR. In order to determine gene cassettes, 
amplified fragments were subjected to DNA sequencing of both amplicon strands. The prevalence of resistance to 
clarithromycin, metronidazole, clarithromycin, tetracycline, amoxicillin, rifampin, and levofloxacin were 68.2% 
(n=75), 25.5% (n=28), 24.5% (n=27), 19.1% (n=21), 18.2% (n=20) and 16.4% (n=18), respectively. Frequency 
of multidrug resistance among H. pylori isolates was 12.7%. Class 2 integron was detected in 50 (45.5%) and 
class 1 integron in 10 (9.1%) H. pylori isolates. The most predominant gene cassette arrays in class 2 integron-
bearing H. pylori were included sat-era-aadA1, dfrA1-sat2-aadA1, blaoxa2 and, aadB whereas common gene 
cassette arrays in class 1 integron were aadB-aadA1-cmlA6, aacA4, blaoxa2, and catB3. The high frequency of 
class 2 integron and multidrug resistance in the present study should be considered as a warning for clinicians 
that continuous surveillance is necessary to prevent the further spread of resistant isolates. 
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countries (Correa and Piazuelo, 2008). The prevalence of 
H. pylori infection varies globally in different populations 
and is associated with geographic area, socioeconomic 
factors, personal hygiene and age. H. pylori infection is 
generally acquired in childhood (Rafeey et al., 2007). 
Treatment of H. pylori infection is recommended in all 
symptomatic individuals, which is the main factor for 
eradication of H. pylori infection. Based on previous 
reports, H. pylori eradication leads to the reduction of the 
severity of gastric disease symptoms, the development 
of atrophic gastritis, the risk of cancer progression and 
complete recovery of patients (Smith et al., 2014). 
Widespread antibiotics use for killing or eradication 
of enteric pathogens and respiratory tract infections 
led to the emergence of MDR to H. pylori. Failure of 
therapy not only leads to worsening of disease but also 
increases the resistance of the bacterium to the prescribed 
antibiotics (Rafeey et al., 2007; Smith et al., 2014). 
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Increase of resistance to therapeutic option of H. pylori 
infection is the most serious problem in eradicating H. 
pylori. Unfortunately, it is documented that in Iran and 
lots of other developing countries, the eradication rate 
of H. pylori is much lower than the rate reported in 
other countries (Milani et al., 2012; Fathi et al., 2013). 
Considering extreme genetic heterogeneity of H. pylori, 
several mechanisms of resistance to antibiotics are 
accurately detailed (point mutations, redox intracellular 
potential, pump efflux systems, membrane permeability 
and penetration of bacterium in the mucous layer of 
stomach) (Nishizawa and Suzuki, 2014). Recently, 
horizontal gene transfer mediated by mobile genetic 
elements, e.g., plasmids, transposons and integrons, 
have been shown to contribute to the spread of antibiotic 
resistance genes among bacteria (Crespo et al., 2005). 
Integrons as a motionless genetic element which consists 
of 5´and 3´-conserved segments with gene cassettes 
containing antibiotic resistance genes are  major elements 
in the spread of MDR particularly in Gram-negative 
species (Gillings, 2014). The basic structure of an integron 
consists of an integrase gene (intI) encoding an integrase, 
a recombination site (attI) and a strong promoter (PC) 
gene that permits the expression of the gene cassettes. 
To date, several classes of integrons have been described 
that are recognized by their distinct integrase genes. 
Class 1 and 2 integrons are the most common and widely 
distributed among gram-negative bacteria isolated from 
clinical samples. Integron gene sequences contribute to 
the spread of antimicrobial resistance alleles by lateral 
gene transfer. Class 2 integrons are embedded in Tn7, 
and are less common than class 1 integrons. Other classes 
of integrons were rarely reported (Cambray et al., 2010; 
Gillings, 2014). According to the literature reviews, the 
prevalence of H. pylori infection is steadily increasing in 
Iran (Rafeey et al., 2007; Milani et al., 2012). In the present 
research, dissemination of different classes of integrons 
and their gene cassettes in H. pylori has been studied for 
the first time in Iran. We also assessed susceptibility of 
H. pylori isolates to the commonly used antibiotics for 
eradication regimens.
Materials and Methods
Sampling and data collection
This cross-sectional study was conducted on 154 
biopsy specimens obtained from patients with suspected 
H. pylori infection who were referred to gastroenterology 
wards of Tehran (capital city of Iran) hospitals during 
a 9-month period from 1 January 2015 to the end of 
September 2015. None of the participants in this study 
had a history of use of non-steroidal anti-inflammatory 
drugs (NSAIDs) and proton pomp inhibitors in three 
weeks before proceeding to endoscopy. Two gastric biopsy 
specimens were taken from each patient. One of them was 
used for rapid urease test and the other was placed in sterile 
tubes containing 10 ml Stuart medium (Merck, Germany) 
and transported to the microbiology laboratory within 4 
h of collection. For bacterial identification, homogenized 
gastric biopsy samples were cultured in Brucella blood 
agar (Merck, Germany) containing defibrinated sheep 
blood (5%) and antibiotic supplements (vancomycin 
5 mg/L, trimethoprim 5 mg/L, and polymyxin B 0.25 
mg/L). The plates were incubated under microaerophilic 
conditions (5% O2, 10% CO
2
, 85% N2) at 37°C and high 
humidity for 3 to 7 days. Organisms were identified as H. 
pylori based on gram stain, culture, oxidase, catalase and 
rapid urease test. Samples confirmed as H. pylori isolates 
were stored in Brain Heart Infusion broth containing 
(BHI; Merck, Germany) containing 30% glycerol at -70°C 
for further studies. The study protocol was approved by 
the Ethics Committee of Shahid Beheshti University of 
Medical Sciences (No. 381).
Antimicrobial susceptibility testing
Pure cultures of H. pylori isolates were used for 
antibiotic susceptibility test. Antimicrobial susceptibility 
of H. pylori isolates was assessed by minimum inhibitory 
concentration (MIC) test according to the guidelines of 
the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) (www.eucast.org). The following 
antimicrobial agents were purchased from Sigma-Aldrich 
(St. Louis, Mo) and used in this study: metronidazole, 
levofloxacin, clarithromycin, amoxicillin, rifampicin 
and tetracycline. Minimum inhibitory concentration 
(MIC) was defined as the lowest concentration of each 
antimicrobial agent that inhibited visible growth of 
the tested isolate. The ranges of MIC value used for 
antimicrobial agents were including: metronidazole 0.25 
to 32 µg/ml; rifampicin 0.25 to 8 µg/ml; clarithromycin 
0.125 to 4 µg/ml; amoxicillin 0.125 to 16; levofloxacin 
0.125 to 4 µg/ml; tetracycline 0.125 to 16 µg/ml. H. 
pylori ATCC 26695 strain was used as the quality-control 
organisms in antimicrobial susceptibility determination. 
MIC50 and MIC90 (MICs that inhibit 50% and 90% of the 
isolates) were estimated for each antibiotic.
Extraction of plasmid and genomic DNA
Genomic DNA was extracted using the QIAamp DNA 
isolation columns (Qiagen, Hilden, Germany) according to 
the manufacturer’s procedure. The Qiagen Plasmid Midi 
Kit was used for plasmid DNA extraction according to 
the manufacturer’s instruction. The concentration of DNA 
was assessed by spectrophotometer. DNA was stored at 
-20°C for further studies.
Detection of integrons and gene cassettes inserted in the 
variable regions
Detection of class 1 and 2 integrons was carried 
out by PCR using degenerate primer sets described by 
Moura et al. which hybridizes to conserve regions of 
integron-encoded genes (Moura et al., 2007). Amplified 
fragments of the class 1 and 2 integrons were 280bp and 
232bp, respectively. PCR was done by thermocycler 
(Eppendorf, Hamburg, Germany) using the following 
modified conditions; initial denaturation for 4 min at 94ºC, 
35 cycles of denaturing at 94ºC for 1 min, annealing at 
57ºC for 45 s, and extension at 72ºC for 45 s. The final 
extension was carried out at 72ºC for 5 min. 
Amplification of the variable region between class 1 
and 2 integrons was performed using degenerated primer 
pairs described by Moura et al., (Moura et al., 2007). 
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PCR products of variable regions were sequenced after 
purification using QIAquick Gel Extraction kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s 
instruction. Purified PCR products of variable regions 
were sequenced by an ABI Prism 377 automated sequencer 
(Applied Biosystems, Perkin-Elmer, Foster City, CA) in 
both directions. The sequences were assembled using 
SeqMan program within the Lasergene suite version 7 
(DNAstar Inc, Madison, WI, USA). The BLAST program 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) was performed 
repeatedly for sequence comparison and annotation.
Statistical analysis
Statistical analysis was performed using the SPSS 
version 18.0 software (SPSS Inc., Chicago, IL). 
Categorical variables were analyzed by Chi-square test. 
A P value ≤ 0.05 was statically significant.
Results 
During the 9-months study period, a total of 154 biopsy 
specimens were taken from patients with suspected H. 
pylori infection and a total of 110 samples (71.4%) were 
H. pylori positive which were entered to the study. In this 
study, 40 (36.4%) patients were females and 70 (63.6%) 
patients were males (age range 34-70 years). Out of 
110 patients entered in the study who were screened, 45 
(40.9%) had gastric cancer, 37 (33.6%) duodenal ulcer, 12 
(10.9%) peptic ulcer, 10 (9.1%) gastric ulcer and 6 (5.5%) 
gastric cancer with peptic ulcer. H. pylori resistance rates 
to antimicrobial agents were as follows: metronidazole 
68.2% (n=75), clarithromycin 25.5% (n=28), tetracycline 
24.5% (n=27), amoxicillin 19.1% (n=21), rifampicin 
18.2% (n=20) and levofloxacin 16.4% (n=18). Out of 75 
isolates resistant to metronidazole, 25 (33.4%) of isolates 
had MIC > 8µg/ml, 10 (13.3%) had MIC ≥ 16µg/ml, 30 
(40%) had MIC ≥ 32µg/ml and 10 (13.3%) had MIC ≥ 
64µg/ml. Of 10 isolates resistant to metronidazole with 
MIC ≥ 64µg/ml, 6 isolates were isolated from patients 
with gastric cancer and peptic ulcer and 4 isolates were 
isolated from patients with gastric cancer. All of the 
metronidazole-resistant strains with MIC ≥ 32µg/ml 
except for seven isolates were isolated from patients 
with gastric cancer. The MIC values of metronidazole 
for the rest of isolates (31.8%, n=35) were ranged from 
0.5 to 4 µg/ml. The results of clarithromycin MIC were 
as follows: 26 (23.6%) of isolates had MIC 0.125 µg/ml, 
56 (51%) had MIC 0.25 µg/ml, 3 (2.7%) had MIC 0. 5 
µg/ml, 10 (9.1%) had MIC 1 µg/ml, 4 (3.6%) had MIC 1 
µg/ml, 5 (4.5%) had MIC 2 µg/ml and 6 (5.5%) had MIC 
4 µg/ml. Of six resistant isolates to clarithromycin with 
MIC ≥ 4µg/ml, three isolates were isolated from patients 
with peptic ulcer and the remaining three isolates were 
obtained from patients with gastric ulcer. As previously 
mentioned, 24.5% of the isolates were resistant to 
tetracycline. Out of 27 resistance isolates to tetracycline, 
20 (74.1%) of isolates had MIC ≥ 2 µg/ml and 7 (25.9%) 
had MIC ≥ 4 µg/ml. All susceptible isolates except two 
of them were inhibited by tetracycline at MIC ≤ 0.5µg/
ml. In our survey, 19.1% of the isolates were resistant to 
amoxicillin (MIC ≥ 2 µg/ml). Out of 21 resistance isolates 
to amoxicillin, 20 (95.2%) of isolates had MIC ≥ 2 µg/
ml, whereas, only one isolate (4.8%) had MIC ≥ 4 µg/ml. 
Out of 21 isolates resistant to amoxicillin, one isolate was 
isolated from patient with gastric cancer, 15 isolates from 
patients with duodenal ulcer and 5 isolates from patients 
with gastric ulcer. All of the H. pylori isolates resistant to 
rifampicin except five isolates (three isolates had MICs ≥ 
2µg/ml and the remaining two isolates had MIC > 1 µg/
ml) were inhibited at MIC ≥ 4 µg/ml. The MIC values 
of rifampicin for remaining 90 (81.8%) of isolates was 
ranged from 0.125 to 1 µg/ml. Out of 20 isolates resistant 
to rifampicin, 15 isolates were isolated from patients with 
gastric cancer, three isolates from patients with duodenal 
ulcer and two isolates from patients with gastric ulcer. 
The lowest level of resistance was related to levofloxacin 
(16.4%). Out of 18 resistance isolates to levofloxacin, 12 
(66.7%) of isolates had MIC ≥ 2 µg/ml and six (33.3%) 
had MIC ≥ 4 µg/ml. Isolates with resistance to levofloxacin 
were isolated from patients with gastric cancer (55.5%), 
duodenal ulcer (27.8%) and peptic ulcer (16.7%). MDR 
was defined as resistance to three or more antibiotics of 
different classes (Boyanova et al., 2015,  http://dx.doi.
org/10.1016/j.ijantimicag.2015.08.010). Frequency of 
MDR in our survey was 12.7%. In particular, 68 (61.8%), 
12 (10.9%) and two isolates (1.8%) were resistant to two, 
three and four different drugs, respectively.
The predominant resistance profile among the studied 
isolates was included resistance to metronidazole and 
tetracycline. Pattern of multiple resistances of 110 H. 
pylori isolates to different antibiotics are showed in 
Table 1. 
Integron was detected in 64 isolates (58.2%). PCR 
results for detection of class 1 and class 2 integrons 
Table 1. Frequency of Multiple Resistance of H. pylori 
isolates to Antimicrobial Agents
Resistance pattern No (%)
MTZa+TETb 25(22.7)
MTZa+LEVc 18(16.4)
MTZa+CLMd 15(13.6)
MTZa+AMXe 10(9.1)
MTZa+CLMd+RIFf 5(4.5)
MTZa+AMXe+CLMd 7(6.3)
MTZa+AMXe+TETb+RIFf 2(1.8)
a Metronidazole; b Tetracycline; c levofloxacin; d clarithromycin; e 
amoxicillin; f rifampicin
Table 2. Frequency of Integron in 110 H. pylori Clinical 
Isolates
Integron class Frequency (%)
Integron class 1 10(9.1%)
Integron class 2 50(45.5%)
Integron class 1 and 2 4(3.6%)
Integron class 3 0(0)
Without integron 46(41.8)
Total 110(100)
Mehdi Goudarzi et al
Asian Pacific Journal of Cancer Prevention, Vol 17, 20163312
revealed a dominant existence of class 2 integron in 50 
(45.5%) H. pylori isolates, whereas class 1 integron was 
detected in 10 isolates (9.1%). Also, co-existence of class 
1 and 2 integrons was detected in four isolates (3.6%). 
Frequency of integrons in 110 H. pylori clinical isolates 
are shown in Table 2. Out of 50 isolates carrying class 2 
integron, 28 isolates (56%) were obtained from patients 
with gastric cancer, 10 isolates (20%) from with duodenal 
ulcer patients, five isolates (10%) from patients with 
peptic ulcer, four isolates (8%) from patients with gastric 
ulcer three isolates (6%) from patients with gastric cancer 
and peptic ulcer. All class 1 integrons bearing isolates 
were isolated from patients with gastric cancer. Class 2 
integrons in 45 (90%) isolates were located on plasmid 
and in five (10%) isolates were located on chromosome 
while integron class 1 in seven isolates (70%) were 
located on chromosome and in 3 isolates (30%) were 
located on plasmid. Integron frequency among resistant 
and susceptible strains is presented in Table3. Common 
gene cassettes arrays in class 2 integron included dfrA1-
sat2-aadA1, Sat-era-aadA1, blaoxa2 and, aadB whereas 
common gene cassettes arrays in class 1 integron included 
aadB-aadA1-cmlA6, aacA4, blaoxa2, and catB3. dfrA1-
sat2-aadA1 gene cassette was detected in 13 integron class 
2-bearing H. pylori strains, Sat-era-aadA1 as a novel gene 
cassette in 12 strains, and blaoxa2 gene cassette (confer 
resistance to oxacillin and ampicillin) in 12 strains. 
aadB gene cassette (confer resistance to gentamicin, 
tobramycin, and kanamycin) was detected in 10 class 2 
integron-bearing H. pylori strains. Three isolates of class 
2 integron-positive harbored no gene cassette. aadB-
aadA1-cmlA6 was detected in 5 integron class 1-bearing 
H. pylori strains (aadA1 confer resistance to streptomycin 
and spectinomycin), aacA4 gene cassette in 2 class 1 
integron -bearing H. pylori strains (confer resistance to 
gentamicin, amikacin and tobramycin resistance) and 
catB3 gene cassette in 3 class 1 integron -bearing H. 
pylori strains (confer resistance to chloramphenicol). All 
the isolates with integron class 1 harbored gene cassette.
Nucleotide sequence accession number
The nucleotide sequence of new cassette array 
obtained from in this study is available in the GenBank 
nucleotide database under accession numbers LC095818. 
It is also available in Integron Database INTEGRALL 
(http://integrall.bio.ua.pt/).
Discussion
In the current study, prevalences of class 1 and 2 
integrons were examined among multidrug resistant 
H. pylori, isolated from 110 patients. The prevalence 
of antimicrobial-resistant H. pylori infection is of 
considerable public health concern especially in 
developing countries (Milani et al., 2012; Fathi et al., 
2013).
Effective therapy plays an important role in the 
eradication of H. pylori-associated disorders. Eradication 
treatment for H. pylori infection requires to combination 
therapy, consisting of one or two antibiotics (amoxicillin, 
metronidazole or clarithromycin) with an acid suppressor 
(usually a proton pump inhibitor) or a histamine receptor 
(H2-receptor) antagonist (e.g. ranitidine) (Correa and 
Piazuelo, 2008; Malfertheiner et al., 2012). According 
to the literature, proper regimen along with improved 
public knowledge of personal hygiene can lead to 85–90% 
eradication rate. Inappropriate use of antimicrobial 
agents, limited therapeutic options, and also emergence 
of MDR strains of H. pylori are considered a major factor 
contributing to treatment failure (Fuccio et al., 2009). 
Therefore, consciousness about H. pylori antibiotic 
resistance pattern is necessary to prescribe the most 
effective therapy regimen and prevent further spread of 
resistant isolates. Antibiotic resistance pattern of H. pylori 
to antimicrobial agents varies in different geographical 
regions and depends on local use of antibiotics (Milani 
et al., 2012). 
According to the literature, the rate of resistance 
to metronidazole in H. pylori that has been reported to 
range between eight and 80% in different countries, 
varies according to geographical region (Nishizawa and 
Suzuki, 2014). Our results showed a very high resistant 
rate to metronidazole (68.2%) among isolates, which 
were significantly higher in female than in male patients. 
In Loffeld et al. (Loffeld and Werdmuller, 2013) study 
in Netherland, antibiotic susceptibility of H. pylori in 
native Dutch patients and patients of Turkish descent was 
determined. They investigated 925 strains of H. pylori 
during a period of eight years. They showed resistance 
to metronidazole in 147 isolates (19.9%). In another 
study conducted in Sofia, Bulgaria in 2015, Boyanova 
et al. evaluated the susceptibility of 53 H. pylori strains 
by Etest. Resistance to metronidazole was reported in 
37.7% of isolates (Boyanova et al., 2015,  http://dx.doi.
org/10.1016/j.ijantimicag.2015.08.010). Goudarzi et al. 
in a study conducted in Iran in 2014, showed that highest 
levels of resistance was related to metronidazole (66.3%) 
(Goudarzi et al., 2015). In Turkey, the rate of resistance to 
metronidazole reported in 35.5% (34/98) of clinical strains 
of H. pylori (Caliskan et al., 2015). Manfredi et al. assessed 
Table 3. Antibiotic Resistance and Integrons in H. pylori Clinical Isolates
Antibiotics
MIC(µg/ml) Antibiotic susceptibility (n=110) Integron positive(n=64) Inetgron negative(n=46)
Range 50% 90% R S R S R Sn (%) n (%) n (%) n (%) n (%) n (%)
metronidazole 0. 25-32 0.5 2 75(68.2) 35(31.8) 63(98.4) 1 (1.6) 12(26.1) 34(73.9)
clarithromycin 0.125-4 1 2 28(25.5) 82(74.5) 14(21.9) 50(78.1) 14(30.4) 32(69.6)
tetracycline 0.125-16 1 1 27(24.5) 83(75.5) 21(32.8) 43(67.2) 6(13) 40(87)
amoxicillin  v 0.5 0.5 21(19.1) 89(80.9) 20(31.3) 44(68.7) 1(2.2) 45(97.8)
rifampicin 0.125-4 0.5 0.5 20(18.2) 90(81.8) 15(23.4) 49(76.6) 5(10.9) 41(89.1)
levofloxacin 0.5-16 0.5 1 18(16.4) 92(83.6) 11(17.2) 53(82.8) 7(15.2) 39(84.8)
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the antimicrobial susceptibility changes in children with 
H. pylori infection in Italy over a 13-year period from 
1998 to 2012. They showed reduction in metronidazole 
resistance from 56% in 1998/99 to 33% in 2011/12 
(Manfredi et al., 2015). High resistance to metronidazole 
among H. pylori clinical isolates has been reported from 
Iran and some other Asian countries. These findings 
about resistance rate to metronidazole in our study were 
consistent with some reports from developing countries 
that described a high level of resistance to metronidazole, 
which varies from 66.2% to 100% (Sherif et al., 2004; 
Aboderin et al., 2007). Overall, in developed countries 
it has been documented that 15.8% to 40% of H. pylori 
strains were resistant to metronidazole (Parsons et al., 
2001; Boyanova et al., 2002). These discrepancies in the 
rate of resistance to metronidazole in our study compared 
to other studies might be explained by the extensive use 
of this antibiotic in treatment of diseases caused by H. 
pylori and common different infections such as protozoal 
diseases, and periodontal or gynaecological infections. 
However, the role of various gene mutations in NADPH 
nitroreductase (RdxA), NADPH-flavin-oxidoreductase 
(FrxA), and ferredoxin likeenzymes (FrxB) should not 
be ignored in resistance to metronidazole (Masaoka et 
al., 2006).
Clarithromycin as the first line therapy against H. 
pylori infections and an essential antibiotic for H. pylori 
treatment has an increased resistance rate from 9% in 
1998 to 17.6% in 2008 in Europe (Asaka et al., 2010). 
The second most resistance, which was identified in 
our study, was resistance to clarithromycin. Of the 
110 H. pylori isolates, 28 (25.5%) showed resistance 
to clarithromycin. These results are in accordance 
with a previous study done in Tehran, Iran in 2014, by 
Goudarzi et al. which showed that the rate of resistance 
to clarithromycin was 18.4% (Goudarzi et al., 2015). 
Furthermore, Loffeld et al. reported a 20.5% resistance 
rate to clarithromycin in their tested isolates (Loffeld 
and Werdmuller, 2013). Overall, compared to performed 
studies in Bulgaria (Boyanova et al., 2015,  http://dx.doi.
org/10.1016/j.ijantimicag.2015.08.010), Brazil (Ogata 
et al., 2014), Netherlands (Loffeld and Werdmuller, 
2013), Italy (Manfredi et al., 2015), Sweden (1.5%), 
and Malaysia (2.1%) (De Francesco et al., 2006), a high 
resistance to clarithromycin was observed in our study. 
These differences in resistance to clarithromycin in our 
study with other studies could be attributed to frequent 
use of macrolides in patients with upper respiratory tract 
infection, the efflux pump system and point mutations. 
Resistance to tetracycline was observed in 24.5% 
of our isolates which was higher than the reported rates 
in Korea (0.5%) (Chung et al., 2012), Bulgaria (1.9%) 
(Boyanova et al., 2015,  http://dx.doi.org/10.1016/j.
ijantimicag.2015.08.010), Turkey (0%) (Caliskan et al., 
2015), Brazil (0%) (Ogata et al., 2014), Germany (0%) 
(Wueppenhorst et al., 2013) and India (4%) (Ahmed et al., 
2012) and lower than the reported rate in Africa (43.9%) 
(De Francesco et al., 2006). In previous study conducted 
in Iran, in 2014, Goudarzi et al., found a low resistance 
rate to tetracycline (3.1%) in H. pylori clinical isolates 
(Goudarzi et al., 2015).
The present study revealed a high resistance rate to 
tetracycline that might be related to a greater use of this 
antibiotic in treatment of most of infections, mutations in 
the 16S rRNA, and horizontal transfers.
In the present survey, we found 21 resistant isolates to 
amoxicillin out of the 110 tested isolates (19.1%). Based 
on the most recent data available from the literature, 
results on amoxicillin resistance are highly contradictory. 
Amoxicillin resistance has fortunately remained low in 
several countries. The low and/or no amoxicillin resistance 
rates are reported in some countries, such as Kuwait 
(John Albert et al., 2006), Senegal (Seck et al., 2009), 
Netherlands (Loffeld and Werdmuller, 2013), Bulgaria 
(Boyanova et al., 2015,  http://dx.doi.org/10.1016/j.
ijantimicag.2015.08.010), Korea (Kim et al., 2006) and 
Turkey (Caliskan et al., 2015). The reported rate in the 
present survey (19.1%) is lower than India (Ahmed et 
al., 2012), China (Wu et al., 2000), Brazil (Godoy et al., 
2003) and Cameroon (Ndip et al., 2008). Reports of Iran 
also showed a wide difference of amoxicillin resistance 
rates; for instance the findings of Milani et al.,(Milani 
et al., 2012) revealed 28.6% resistance to amoxicillin 
while in the same context, goudarzi et al., (Goudarzi et 
al., 2015) reported amoxicillin resistance in 5.1% of the 
strains. This wide variation in amoxicillin resistance rates 
reported from different countries may be the consequence 
of misuse and overuse of this antibiotic, point mutation 
on pbp1, β-lactamase production. The rate of resistance to 
levofloxacin in the study was relatively low (16.4%). This 
result was strongly supported by the findings of Bulgaria 
(Boyanova et al., 2015,  http://dx.doi.org/10.1016/j.
ijantimicag.2015.08.010), Japan (Kobayashi et al., 
2007) and Taiwan (Hu et al., 2007). Although, the rate of 
resistance to levofloxacin differ  in different countries, the 
results of the present study in comparison with previous 
study conducted in Iran revealed the rapid emergence of 
levofloxacin resistance in H. pylori.
The present study revealed that 12.7% of isolates 
were MDR. The incidence of multiple resistance of H. 
pylori isolates to common therapeutic agents was in 
agreement with Milani et al. (Milani et al., 2012) who 
reported ten of examined 112 strains (9%) were resistant 
to four antibiotics and 4 of examined 112 strains (3.6%) 
were resistant to more than 4 antibiotics. Our study 
showed a high carrier rate of plasmid (75%) among H. 
pylori harboring integron. This result was supported by 
the findings of Crespo et al. (Crespo et al., 2005) who 
believed Tn7 could be probably located in plasmid DNA 
and confirmed antimicrobial resistance in H. pylori strains.
To our knowledge, this is the first study to report 
carriage of class 1 and 2 integrons and associated gene 
cassettes in H. pylori isolates from Iran. It is noteworthy 
that a dominant existence of class 2 integron 50 (45.5%) 
was seen in our H. pylori isolates. This finding is in 
consistent with a study conducted by Crespo et al. in 
Argentina that revealed a high carrier rate (37.5%) of 
integron class 2 in clinical isolates of H. pylori (Crespo 
et al., 2005). 
A study conducted in China in order to investigate 
the status of the plasmid and classes 1-3 integrons in 
metronidazole resistant H. pylori strains isolated from a 
Mehdi Goudarzi et al
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region at high risk of gastric cancer. Yue et al. (Yue et al., 
2014) detected resistance to metronidazole in 88 isolates 
(51.16%) meanwhile none of isolates carried integron 
gene even on plasmid. This discrepancy in frequency of 
integron and gene cassettes in H. pylori isolates could 
be explained by overuse of antibiotics for treatment 
gastrointestinal disorders, various treatment protocols 
applied in different geographic regions and the ability 
of H. pylori isolates in horizontal gene transfer among 
susceptible and resistant strains. 
This survey elucidated a high prevalence of antibiotic 
resistance in H. pylori isolates in Iran. According to 
our findings, metronidazole is not an effective drug 
for treatment of H. pylori infections. Clinicians must 
consider that guidelines for the management of H. pylori 
infection should be revised. Established therapies should 
be recommended in order to successful eradication of H. 
pylori infections. Although the main cause of antibiotic 
resistances in H. pylori may be induced by de novo, it 
can be justified by horizontal gene transfer as well. High 
frequency of class 2 integron with diverse cassette arrays 
play a role as a genetic reservoir for the dissemination 
of antimicrobial resistance gene and could be a severe 
problem for H. pylori treatment.
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